recombinant murine vegf-a isoforms 164 Search Results


recombinant mouse vegf 164 protein  (Bio-Techne corporation)
95
Bio-Techne corporation recombinant mouse vegf 164 protein
Recombinant Mouse Vegf 164 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/Recombinant+Mouse+VEGF+164+Protein/bio-techne+corporation___493-mv
Average 95 stars, based on 1 article reviews
recombinant mouse vegf 164 protein - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
human vascular endothelial growth factor vegf a  (R&D Systems)
96
R&D Systems human vascular endothelial growth factor vegf a
Figure 3. Metalloproteinase-dependent crosstalk between VEGFR2 and ERK signaling. A, Western blot of a time course of ERK1/2 phosphorylation in HUVECs treated with or without <t>VEGF-A</t> or VEGF-A and MM (2 mol/L), with total ERK1/2 as load- ing control. B, Shedding of AP-tagged neuregulin 11 or -12 or EGF from PAE-KDR cells treated with or without VEGF-A. C, Shedding of HB-EGF–AP from PAE-KDR cells treated with or with- out VEGF-A or with VEGF-A and MM (2 mol/L), U0126 (10 mol/ L), or SB202190 (10 mol/L) (n3, SD).
Human Vascular Endothelial Growth Factor Vegf A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/Endothelial+Cell+Growth+Media+without+VEGF/10__1161_slash_circresaha__108__184416-160-3-12
Average 96 stars, based on 1 article reviews
human vascular endothelial growth factor vegf a - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
recombinant murine vegf a  (R&D Systems)
93
R&D Systems recombinant murine vegf a
Figure 3. Metalloproteinase-dependent crosstalk between VEGFR2 and ERK signaling. A, Western blot of a time course of ERK1/2 phosphorylation in HUVECs treated with or without <t>VEGF-A</t> or VEGF-A and MM (2 mol/L), with total ERK1/2 as load- ing control. B, Shedding of AP-tagged neuregulin 11 or -12 or EGF from PAE-KDR cells treated with or without VEGF-A. C, Shedding of HB-EGF–AP from PAE-KDR cells treated with or with- out VEGF-A or with VEGF-A and MM (2 mol/L), U0126 (10 mol/ L), or SB202190 (10 mol/L) (n3, SD).
Recombinant Murine Vegf A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/Recombinant+Canine+VEGF+Protein%2C+CF/10__1161_slash_circresaha__109__207415-361-0-8
Average 93 stars, based on 1 article reviews
recombinant murine vegf a - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
recombinant murine vascular endothelial growth factor (vegf -164  (Biomol GmbH)
90
Biomol GmbH recombinant murine vascular endothelial growth factor (vegf -164
Figure 3. Metalloproteinase-dependent crosstalk between VEGFR2 and ERK signaling. A, Western blot of a time course of ERK1/2 phosphorylation in HUVECs treated with or without <t>VEGF-A</t> or VEGF-A and MM (2 mol/L), with total ERK1/2 as load- ing control. B, Shedding of AP-tagged neuregulin 11 or -12 or EGF from PAE-KDR cells treated with or without VEGF-A. C, Shedding of HB-EGF–AP from PAE-KDR cells treated with or with- out VEGF-A or with VEGF-A and MM (2 mol/L), U0126 (10 mol/ L), or SB202190 (10 mol/L) (n3, SD).
Recombinant Murine Vascular Endothelial Growth Factor (Vegf 164, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/recombinant+murine+vascular+endothelial+growth+factor++vegf++164/pmc02607016-110-3-19
Average 90 stars, based on 1 article reviews
recombinant murine vascular endothelial growth factor (vegf -164 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant full-length murine cyr61  (Abnova)
90
Abnova recombinant full-length murine cyr61
<t>Cyr61</t> knockdown in mature osteoblasts and osteocytes results in decreased trabecular and cortical bone. (A) eGFP immunostaining in Cyr61eGFP mice; expression was seen in bone lining cells (white arrowheads), cuboidal osteoblasts (red arrow), trabecular osteocytes (white arrows), and cortical osteocytes (orange arrows). (B) µCT cross-sectional images and 3D reconstructions of the distal femurs of 3-month-old WT and Cyr61OCN mice (n = 6). (C–H) µCT analysis of trabecular bone showed significantly lower BMD, BV/TV, Tb.BS, Tb.Th, and Tb.N, as well as an increase in Tb.Sp (n = 6). (I) µCT cross-sectional images of mid-shafts of the femurs of WT and Cyr61OCN mice, (J, K) showed decreases in Ct.Th and BV in Cyr61OCN mice (n = 6). (L) Mechanical testing of the femurs of Cyr61OCN mice revealed significantly lower peak force as well as fail force during three-point bending tests as compared to control littermates (n = 6). BMD = bone mineral density; BV/TV = trabecular bone volume to total bone; Tb.BS = trabecular bone surface area; Tb.Th = trabecular bone thickness; Tb.N = trabecular bone number; Tb.Sp = trabecular bone spacing; Ct.Th = cortical bone thickness; BV = bone volume.
Recombinant Full Length Murine Cyr61, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/recombinant+human+cyr61/pmc06002906-153-0-6
Average 90 stars, based on 1 article reviews
recombinant full-length murine cyr61 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant human fibroblast growth factor-b (fgf-b)  (Biomol GmbH)
90
Biomol GmbH recombinant human fibroblast growth factor-b (fgf-b)
<t>Cyr61</t> knockdown in mature osteoblasts and osteocytes results in decreased trabecular and cortical bone. (A) eGFP immunostaining in Cyr61eGFP mice; expression was seen in bone lining cells (white arrowheads), cuboidal osteoblasts (red arrow), trabecular osteocytes (white arrows), and cortical osteocytes (orange arrows). (B) µCT cross-sectional images and 3D reconstructions of the distal femurs of 3-month-old WT and Cyr61OCN mice (n = 6). (C–H) µCT analysis of trabecular bone showed significantly lower BMD, BV/TV, Tb.BS, Tb.Th, and Tb.N, as well as an increase in Tb.Sp (n = 6). (I) µCT cross-sectional images of mid-shafts of the femurs of WT and Cyr61OCN mice, (J, K) showed decreases in Ct.Th and BV in Cyr61OCN mice (n = 6). (L) Mechanical testing of the femurs of Cyr61OCN mice revealed significantly lower peak force as well as fail force during three-point bending tests as compared to control littermates (n = 6). BMD = bone mineral density; BV/TV = trabecular bone volume to total bone; Tb.BS = trabecular bone surface area; Tb.Th = trabecular bone thickness; Tb.N = trabecular bone number; Tb.Sp = trabecular bone spacing; Ct.Th = cortical bone thickness; BV = bone volume.
Recombinant Human Fibroblast Growth Factor B (Fgf B), supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/fibroblast+growth+factor/pmc02607016-110-13-19
Average 90 stars, based on 1 article reviews
recombinant human fibroblast growth factor-b (fgf-b) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant mouse vegf 164 protein, cf  (Bio-Techne corporation)
93
Bio-Techne corporation recombinant mouse vegf 164 protein, cf
<t>Cyr61</t> knockdown in mature osteoblasts and osteocytes results in decreased trabecular and cortical bone. (A) eGFP immunostaining in Cyr61eGFP mice; expression was seen in bone lining cells (white arrowheads), cuboidal osteoblasts (red arrow), trabecular osteocytes (white arrows), and cortical osteocytes (orange arrows). (B) µCT cross-sectional images and 3D reconstructions of the distal femurs of 3-month-old WT and Cyr61OCN mice (n = 6). (C–H) µCT analysis of trabecular bone showed significantly lower BMD, BV/TV, Tb.BS, Tb.Th, and Tb.N, as well as an increase in Tb.Sp (n = 6). (I) µCT cross-sectional images of mid-shafts of the femurs of WT and Cyr61OCN mice, (J, K) showed decreases in Ct.Th and BV in Cyr61OCN mice (n = 6). (L) Mechanical testing of the femurs of Cyr61OCN mice revealed significantly lower peak force as well as fail force during three-point bending tests as compared to control littermates (n = 6). BMD = bone mineral density; BV/TV = trabecular bone volume to total bone; Tb.BS = trabecular bone surface area; Tb.Th = trabecular bone thickness; Tb.N = trabecular bone number; Tb.Sp = trabecular bone spacing; Ct.Th = cortical bone thickness; BV = bone volume.
Recombinant Mouse Vegf 164 Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/Recombinant+Mouse+VEGF+164+Protein%2C+CF/bio-techne+corporation___493-mv-cf
Average 93 stars, based on 1 article reviews
recombinant mouse vegf 164 protein, cf - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
anti vegf a polyclonal antibody  (OriGene)
90
OriGene anti vegf a polyclonal antibody
<t>Cyr61</t> knockdown in mature osteoblasts and osteocytes results in decreased trabecular and cortical bone. (A) eGFP immunostaining in Cyr61eGFP mice; expression was seen in bone lining cells (white arrowheads), cuboidal osteoblasts (red arrow), trabecular osteocytes (white arrows), and cortical osteocytes (orange arrows). (B) µCT cross-sectional images and 3D reconstructions of the distal femurs of 3-month-old WT and Cyr61OCN mice (n = 6). (C–H) µCT analysis of trabecular bone showed significantly lower BMD, BV/TV, Tb.BS, Tb.Th, and Tb.N, as well as an increase in Tb.Sp (n = 6). (I) µCT cross-sectional images of mid-shafts of the femurs of WT and Cyr61OCN mice, (J, K) showed decreases in Ct.Th and BV in Cyr61OCN mice (n = 6). (L) Mechanical testing of the femurs of Cyr61OCN mice revealed significantly lower peak force as well as fail force during three-point bending tests as compared to control littermates (n = 6). BMD = bone mineral density; BV/TV = trabecular bone volume to total bone; Tb.BS = trabecular bone surface area; Tb.Th = trabecular bone thickness; Tb.N = trabecular bone number; Tb.Sp = trabecular bone spacing; Ct.Th = cortical bone thickness; BV = bone volume.
Anti Vegf A Polyclonal Antibody, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/Vegfa+Rabbit+Polyclonal+Antibody/pm28445620-100-19-24
Average 90 stars, based on 1 article reviews
anti vegf a polyclonal antibody - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rat vegf c  (Aviva Systems)
90
Aviva Systems rat vegf c
<t>Cyr61</t> knockdown in mature osteoblasts and osteocytes results in decreased trabecular and cortical bone. (A) eGFP immunostaining in Cyr61eGFP mice; expression was seen in bone lining cells (white arrowheads), cuboidal osteoblasts (red arrow), trabecular osteocytes (white arrows), and cortical osteocytes (orange arrows). (B) µCT cross-sectional images and 3D reconstructions of the distal femurs of 3-month-old WT and Cyr61OCN mice (n = 6). (C–H) µCT analysis of trabecular bone showed significantly lower BMD, BV/TV, Tb.BS, Tb.Th, and Tb.N, as well as an increase in Tb.Sp (n = 6). (I) µCT cross-sectional images of mid-shafts of the femurs of WT and Cyr61OCN mice, (J, K) showed decreases in Ct.Th and BV in Cyr61OCN mice (n = 6). (L) Mechanical testing of the femurs of Cyr61OCN mice revealed significantly lower peak force as well as fail force during three-point bending tests as compared to control littermates (n = 6). BMD = bone mineral density; BV/TV = trabecular bone volume to total bone; Tb.BS = trabecular bone surface area; Tb.Th = trabecular bone thickness; Tb.N = trabecular bone number; Tb.Sp = trabecular bone spacing; Ct.Th = cortical bone thickness; BV = bone volume.
Rat Vegf C, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/VEGF+C+Rat+(152+a%2Ea%2E)+-+Recombinant+Rat+Vascular+Endothelial+Growth+Factor-C+(152)/10__1172_slash_jci46116-358-16-18
Average 90 stars, based on 1 article reviews
rat vegf c - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
bevacizumab avastin  (Genentech inc)
90
Genentech inc bevacizumab avastin
Mean intraocular pressure at baseline and various postoperative intervals in group 1 <t>(bevacizumab)</t> and group 2 (balanced salt solution).
Bevacizumab Avastin, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/bevacizumab+avastin/pmc04074470-49-0-2
Average 90 stars, based on 1 article reviews
bevacizumab avastin - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
ranibizumab lucentis antibody  (Genentech inc)
90
Genentech inc ranibizumab lucentis antibody
Mean intraocular pressure at baseline and various postoperative intervals in group 1 <t>(bevacizumab)</t> and group 2 (balanced salt solution).
Ranibizumab Lucentis Antibody, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+murine+vegf-a+isoforms+164/ranibizumab++lucentis+antibody/pmc05710306-80-0-2
Average 90 stars, based on 1 article reviews
ranibizumab lucentis antibody - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Figure 3. Metalloproteinase-dependent crosstalk between VEGFR2 and ERK signaling. A, Western blot of a time course of ERK1/2 phosphorylation in HUVECs treated with or without VEGF-A or VEGF-A and MM (2 mol/L), with total ERK1/2 as load- ing control. B, Shedding of AP-tagged neuregulin 11 or -12 or EGF from PAE-KDR cells treated with or without VEGF-A. C, Shedding of HB-EGF–AP from PAE-KDR cells treated with or with- out VEGF-A or with VEGF-A and MM (2 mol/L), U0126 (10 mol/ L), or SB202190 (10 mol/L) (n3, SD).

Journal: Circulation Research

Article Title: VEGF-A Stimulates ADAM17-Dependent Shedding of VEGFR2 and Crosstalk Between VEGFR2 and ERK Signaling

doi: 10.1161/circresaha.108.184416

Figure Lengend Snippet: Figure 3. Metalloproteinase-dependent crosstalk between VEGFR2 and ERK signaling. A, Western blot of a time course of ERK1/2 phosphorylation in HUVECs treated with or without VEGF-A or VEGF-A and MM (2 mol/L), with total ERK1/2 as load- ing control. B, Shedding of AP-tagged neuregulin 11 or -12 or EGF from PAE-KDR cells treated with or without VEGF-A. C, Shedding of HB-EGF–AP from PAE-KDR cells treated with or with- out VEGF-A or with VEGF-A and MM (2 mol/L), U0126 (10 mol/ L), or SB202190 (10 mol/L) (n3, SD).

Article Snippet: Recombinant murine and human vascular endothelial growth factor (VEGF-A) were obtained from R&D Systems (Minneapolis, MN) and used at a concentration of 50 ng/ml.

Techniques: Western Blot, Phospho-proteomics, Control

Cyr61 knockdown in mature osteoblasts and osteocytes results in decreased trabecular and cortical bone. (A) eGFP immunostaining in Cyr61eGFP mice; expression was seen in bone lining cells (white arrowheads), cuboidal osteoblasts (red arrow), trabecular osteocytes (white arrows), and cortical osteocytes (orange arrows). (B) µCT cross-sectional images and 3D reconstructions of the distal femurs of 3-month-old WT and Cyr61OCN mice (n = 6). (C–H) µCT analysis of trabecular bone showed significantly lower BMD, BV/TV, Tb.BS, Tb.Th, and Tb.N, as well as an increase in Tb.Sp (n = 6). (I) µCT cross-sectional images of mid-shafts of the femurs of WT and Cyr61OCN mice, (J, K) showed decreases in Ct.Th and BV in Cyr61OCN mice (n = 6). (L) Mechanical testing of the femurs of Cyr61OCN mice revealed significantly lower peak force as well as fail force during three-point bending tests as compared to control littermates (n = 6). BMD = bone mineral density; BV/TV = trabecular bone volume to total bone; Tb.BS = trabecular bone surface area; Tb.Th = trabecular bone thickness; Tb.N = trabecular bone number; Tb.Sp = trabecular bone spacing; Ct.Th = cortical bone thickness; BV = bone volume.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Article Title: CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance

doi: 10.1002/jbmr.3394

Figure Lengend Snippet: Cyr61 knockdown in mature osteoblasts and osteocytes results in decreased trabecular and cortical bone. (A) eGFP immunostaining in Cyr61eGFP mice; expression was seen in bone lining cells (white arrowheads), cuboidal osteoblasts (red arrow), trabecular osteocytes (white arrows), and cortical osteocytes (orange arrows). (B) µCT cross-sectional images and 3D reconstructions of the distal femurs of 3-month-old WT and Cyr61OCN mice (n = 6). (C–H) µCT analysis of trabecular bone showed significantly lower BMD, BV/TV, Tb.BS, Tb.Th, and Tb.N, as well as an increase in Tb.Sp (n = 6). (I) µCT cross-sectional images of mid-shafts of the femurs of WT and Cyr61OCN mice, (J, K) showed decreases in Ct.Th and BV in Cyr61OCN mice (n = 6). (L) Mechanical testing of the femurs of Cyr61OCN mice revealed significantly lower peak force as well as fail force during three-point bending tests as compared to control littermates (n = 6). BMD = bone mineral density; BV/TV = trabecular bone volume to total bone; Tb.BS = trabecular bone surface area; Tb.Th = trabecular bone thickness; Tb.N = trabecular bone number; Tb.Sp = trabecular bone spacing; Ct.Th = cortical bone thickness; BV = bone volume.

Article Snippet: Recombinant full-length murine Cyr61 was from Abnova, Inc. (Taiwan) and recombinant murine Vegf-A was from R&D Systems, Inc (Minneapolis, MN, USA).

Techniques: Knockdown, Immunostaining, Expressing, Control

Cyr61OCN mice have decreased vasculature and VegfA expression. (A) PECAM immunostaining of 1-month-old mice demonstrating a slight decrease in vasculature at the chondro-osseous junctions in Cyr61OCN mice compared to control (Cyr61fx/fx) littermates. (B) VegfA mRNA expression of 3-month-old cortical bone was decreased more than twofold in Cyr61OCN mice as compared to control littermates (n = 6). (C) Microfil-perfusion angiograms of proximal tibia in 1 month old mice showed a significant decrease in vessel volume (D) in Cyr61OCN mice (n = 4). (E) Ex vivo fetal (E17.5) metatarsal blood vessel outgrowth assay demonstrated a considerable decrease in vascular outgrowth from Cyr61OCN mice compared to WT (Cyr61fx/fx) littermates. This decrease in vessel outgrowth was rescued by addition of exogenous VEGF (n = 4). (F) Deletion of Cyr61 using AdCre resulted in a significant decrease in VegfA expression in vitro (n = 3).

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Article Title: CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance

doi: 10.1002/jbmr.3394

Figure Lengend Snippet: Cyr61OCN mice have decreased vasculature and VegfA expression. (A) PECAM immunostaining of 1-month-old mice demonstrating a slight decrease in vasculature at the chondro-osseous junctions in Cyr61OCN mice compared to control (Cyr61fx/fx) littermates. (B) VegfA mRNA expression of 3-month-old cortical bone was decreased more than twofold in Cyr61OCN mice as compared to control littermates (n = 6). (C) Microfil-perfusion angiograms of proximal tibia in 1 month old mice showed a significant decrease in vessel volume (D) in Cyr61OCN mice (n = 4). (E) Ex vivo fetal (E17.5) metatarsal blood vessel outgrowth assay demonstrated a considerable decrease in vascular outgrowth from Cyr61OCN mice compared to WT (Cyr61fx/fx) littermates. This decrease in vessel outgrowth was rescued by addition of exogenous VEGF (n = 4). (F) Deletion of Cyr61 using AdCre resulted in a significant decrease in VegfA expression in vitro (n = 3).

Article Snippet: Recombinant full-length murine Cyr61 was from Abnova, Inc. (Taiwan) and recombinant murine Vegf-A was from R&D Systems, Inc (Minneapolis, MN, USA).

Techniques: Expressing, Immunostaining, Control, Ex Vivo, In Vitro

Cyr61 inhibits Sost expression in vitro. (A) Cyr61 was significantly suppressed in UMR106 knockdown cells as compared to control (n = 3). (B, C) Cyr61 knockdown (Cyr61-kd) in UMR106 osteoblasts led to a significant decrease in Cyr61, increase in (B) Sost and (C) Mef2c expression. Rescue with AdCYR61 resulted in a significant decrease in Sost and Mef2c expression in both Cyr61-kd and control cells. *p < 0.05 AdGDF versus AdCYR61; #p < 0.05 UMR106::AdGFP versus Cyr61-kd cells (n = 3). (D) Successful knockdown of Sost using siRNA in Cyr61-kd cells and control cells (n = 3). (E) qRT-PCR analysis of Axin2 mRNA expression in UMR106 control and Cyr61-kd cells demonstrates that knockdown of Sost rescues Wnt responsiveness in Cyr61-kd cells (n = 3). AdCYR61 = Cyr61 adenovirus.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Article Title: CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance

doi: 10.1002/jbmr.3394

Figure Lengend Snippet: Cyr61 inhibits Sost expression in vitro. (A) Cyr61 was significantly suppressed in UMR106 knockdown cells as compared to control (n = 3). (B, C) Cyr61 knockdown (Cyr61-kd) in UMR106 osteoblasts led to a significant decrease in Cyr61, increase in (B) Sost and (C) Mef2c expression. Rescue with AdCYR61 resulted in a significant decrease in Sost and Mef2c expression in both Cyr61-kd and control cells. *p < 0.05 AdGDF versus AdCYR61; #p < 0.05 UMR106::AdGFP versus Cyr61-kd cells (n = 3). (D) Successful knockdown of Sost using siRNA in Cyr61-kd cells and control cells (n = 3). (E) qRT-PCR analysis of Axin2 mRNA expression in UMR106 control and Cyr61-kd cells demonstrates that knockdown of Sost rescues Wnt responsiveness in Cyr61-kd cells (n = 3). AdCYR61 = Cyr61 adenovirus.

Article Snippet: Recombinant full-length murine Cyr61 was from Abnova, Inc. (Taiwan) and recombinant murine Vegf-A was from R&D Systems, Inc (Minneapolis, MN, USA).

Techniques: Expressing, In Vitro, Knockdown, Control, Quantitative RT-PCR

Proposed mechanism of Cyr61 modulation of bone mass via regulation of Sost expression.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Article Title: CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance

doi: 10.1002/jbmr.3394

Figure Lengend Snippet: Proposed mechanism of Cyr61 modulation of bone mass via regulation of Sost expression.

Article Snippet: Recombinant full-length murine Cyr61 was from Abnova, Inc. (Taiwan) and recombinant murine Vegf-A was from R&D Systems, Inc (Minneapolis, MN, USA).

Techniques: Expressing

Mean intraocular pressure at baseline and various postoperative intervals in group 1 (bevacizumab) and group 2 (balanced salt solution).

Journal: Journal of Ophthalmic & Vision Research

Article Title: Subconjunctival Bevacizumab for Primary Pterygium Excision; a Randomized Clinical Trial

doi:

Figure Lengend Snippet: Mean intraocular pressure at baseline and various postoperative intervals in group 1 (bevacizumab) and group 2 (balanced salt solution).

Article Snippet: Bevacizumab (Avastin; Genentech Inc., San Francisco, California, USA) a recombinant humanized murine monoclonal immunoglobulin G1 (IgG1), inhibits the VEGF-A isoform, the main stimulant of angiogenesis.

Techniques: